{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-091625","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2026-08-06T11:12:23+00:00","discovered_at":"2026-08-06T11:15:03.438163+00:00","generated_at":"2026-08-06T11:15:14.659759+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ironwood raises FY2026 guidance after strong Q2; LINZESS sales up 44% YTD","bullets":["Q2 total revenue $113M, GAAP net income $51M ($0.31 diluted EPS), adjusted EBITDA $83M.","LINZESS U.S. net sales Q2 $282M, YTD $555M (+44% YoY).","FY2026 guidance raised: LINZESS net sales $1.15-1.20B, total revenue $460-485M, adjusted EBITDA >$310M.","Repaid $200M convertible notes with cash on hand; balance sheet strengthening.","Confirmatory Phase 3 STARS-2 trial of apraglutide in SBS-IF actively recruiting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-091625","json":"https://secwatch.observer/filing/0001104659-26-091625.json","markdown":"https://secwatch.observer/filing/0001104659-26-091625.md","text":"https://secwatch.observer/filing/0001104659-26-091625.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465926091625/0001104659-26-091625-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465926091625/tm2622244d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:15:14.659759+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}